Pericarditis Drugs Global Market Report 2026

Pericarditis drugs are medications designed to treat inflammation and pain in the pericardium, the membrane surrounding the heart. They work by regulating inflammatory responses and relieving discomfort, supporting normal heart function and preventing additional complications. Healthcare professionals prescribe and monitor these drugs to ensure effective treatment while minimizing potential side effects.

The main drug classes in pericarditis treatment include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, corticosteroids, and others. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to reduce inflammation, relieve pain, and lower fever in pericarditis by inhibiting cyclooxygenase enzymes involved in prostaglandin production. These drugs can be administered orally, intravenously, intramuscularly, or topically, and are distributed through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. They are applied in therapeutic areas including acute pericarditis treatment, management of recurrent pericarditis, post-cardiac surgery care, and pericardial effusion management. The primary end users include hospitals, homecare services, specialty clinics, and others.

Tariffs are impacting the pericarditis drugs market by increasing costs of imported active pharmaceutical ingredients, excipients, biologic compounds, and sterile manufacturing inputs. Europe and North America are most affected due to dependence on global API supply chains, while Asia-Pacific faces cost pressures on pharmaceutical exports. These tariffs are contributing to higher drug production costs and influencing hospital procurement budgets. However, they are also encouraging domestic API manufacturing, regional supply chain diversification, and increased investment in localized pharmaceutical production capabilities.

The pericarditis drugs market research report is one of a series of new reports from The Business Research Company that provides pericarditis drugs market statistics, including pericarditis drugs industry global market size, regional shares, competitors with a pericarditis drugs market share, detailed pericarditis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the pericarditis drugs industry. This pericarditis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pericarditis drugs market size has grown strongly in recent years. It will grow from $3.31 billion in 2025 to $3.61 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing diagnosis rates of inflammatory cardiac conditions, availability of established NSAID therapies, expansion of cardiology care infrastructure, growing use of colchicine-based treatments, improved clinical guidelines.

The pericarditis drugs market size is expected to see strong growth in the next few years. It will grow to $5.1 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to increasing development of biologic and immunomodulatory drugs, rising focus on personalized cardiac care, expansion of outpatient and homecare treatment models, growing investment in cardiovascular research, increasing awareness of rare inflammatory heart diseases. Major trends in the forecast period include increasing adoption of targeted anti-inflammatory therapies, rising use of combination drug regimens, growing focus on recurrent pericarditis management, expansion of hospital-based treatment protocols, enhanced monitoring of treatment outcomes.

The rising prevalence of autoimmune diseases is expected to drive the growth of the pericarditis drugs market in the coming years. Autoimmune diseases are conditions where the immune system mistakenly attacks the body's own healthy cells and tissues. This increasing prevalence is mainly influenced by environmental factors that disrupt the immune system, causing it to target healthy tissues. Pericarditis drugs are important in the context of this trend, as many autoimmune conditions can lead to pericarditis, an inflammation of the heart's lining. These drugs help reduce inflammation, alleviate symptoms, and prevent complications, thereby managing pericarditis that results from autoimmune activity. For example, in September 2023, according to the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based organization focused on improving the lives of patients with Crohn's disease and ulcerative colitis, the prevalence of IBD was 825 per 100,000, with over 320,000 people affected in Canada. With an expected annual increase of 2.44%, or 1.1% of the population, approximately 470,000 Canadians are projected to be living with IBD by 2035. Thus, the growing prevalence of autoimmune diseases is contributing to the expansion of the pericarditis drugs market.

The increasing demand for personalized medicine is expected to drive the growth of the pericarditis drugs market in the coming years. Personalized medicine is a healthcare approach that tailors disease prevention and treatment according to an individual's specific genes, behaviors, and environment. The growing interest in personalized treatments is fueling the expansion of personalized medicine, as patients and healthcare providers increasingly seek therapies customized to individual genetic and lifestyle profiles for enhanced effectiveness and minimized side effects. This demand for personalized medicine also drives the need for pericarditis drugs, as it allows for the development of targeted therapies designed according to an individual's genetic and biological profile, resulting in more precise and effective treatment of pericardial inflammation. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA approved 16 personalized therapies targeting rare diseases in 2023, a significant increase from the six approvals issued in 2022. Thus, the growing demand for personalized medicine is supporting the expansion of the pericarditis drugs market.

Major companies operating in the pericarditis drugs market are focusing on developing innovative products, such as oral anti-inflammatory therapies to enhance treatment accessibility and reduce recurrence rates in patients with recurrent pericarditis. An oral anti-inflammatory therapy is a small-molecule formulation designed to modulate inflammatory pathways and prevent disease relapse through systemic, non-injectable administration. For instance, in April 2025, Cardiol Therapeutics Inc., a Canada-based clinical-stage life sciences company specializing in anti-inflammatory and anti-fibrotic therapies for heart diseases, initiated a Phase III clinical trial for CardiolRx. The investigational therapy is designed to target inflammasome pathway activation, a central mechanism in pericarditis-related inflammation and fibrosis. Its development marks progress toward offering a convenient, oral, non-immunosuppressive treatment option that could broaden therapeutic choices for recurrent pericarditis patients.

Major companies operating in the pericarditis drugs market are Merck & Co. Inc., Pfizer Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Hikma Pharmaceuticals USA Inc., Zydus Lifesciences Limited, Kiniksa Pharmaceuticals, Camber Pharmaceuticals Inc., Scilex Holding Company, Solara Active Pharma Sciences, Alkaloids Bioactives Pvt. Ltd., Alchem International Pvt. Ltd., Sarv Biolabs Pvt. Ltd., Midas Pharma GmbH, AdvaCare Pharma, Actavis GmbH, Enomark LLC, Honour Lab Limited.

North America was the largest region in the pericarditis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pericarditis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pericarditis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pericarditis drugs market consists of sales of antitubercular drugs, receptor antagonists, rilonacept, antibiotics or antifungals. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pericarditis Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses pericarditis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pericarditis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pericarditis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Colchicine; Corticosteroids; Other Drug Class
• 2) By Route Of Administration: Oral; Intravenous; Intramuscular; Topical
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 4) By Therapeutic Application: Acute Pericarditis Treatment; Recurrent Pericarditis Management; Post-Cardiac Surgery; Pericardial Effusion Management
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Nonsteroidal Anti-Inflammatory Drugs: Ibuprofen; Aspirin; Indomethacin; Naproxen; Diclofenac
• 2) By Colchicine: Oral Colchicine; Intravenous Colchicine
• 3) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone
• 4) By Other Drug Class: Immunosuppressive Agents; Biologic Agents; Analgesics; Antibiotics
• Companies Mentioned: Merck & Co. Inc.; Pfizer Inc.; Bayer AG; Novartis AG; Bristol-Myers Squibb Company; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Limited; Hikma Pharmaceuticals USA Inc.; Zydus Lifesciences Limited; Kiniksa Pharmaceuticals; Camber Pharmaceuticals Inc.; Scilex Holding Company; Solara Active Pharma Sciences; Alkaloids Bioactives Pvt. Ltd.; Alchem International Pvt. Ltd.; Sarv Biolabs Pvt. Ltd.; Midas Pharma GmbH; AdvaCare Pharma; Actavis GmbH; Enomark LLC; Honour Lab Limited.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.